A. Goto

发表

Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation

J. DeJongh, T. Tsukamoto, S. Asahi, 2017, Biopharmaceutics & drug disposition.

Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK‐357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation

J. DeJongh, T. Tsukamoto, S. Asahi, 2017, Biopharmaceutics & drug disposition.

Development of a bioanalytical method for circulating human T cells in animals using Arthrobacter luteus-based quantitative polymerase chain reaction and its application in preclinical biodistribution studies

H. Hirabayashi, T. Higuchi, Syunsuke Yamamoto, 2020, Regenerative therapy.

Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).

S. Koshiba, A. Goto, N. Sato, 2019, Drug metabolism and pharmacokinetics.

Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells

H. Hirabayashi, Syunsuke Yamamoto, A. Goto, 2020, Scientific Reports.

Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood–Brain Barrier of Mice

H. Kusuhara, A. Oda, M. Nishikawa, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives

S. Iwasaki, Syunsuke Yamamoto, A. Goto, 2022, Biopharmaceutics & drug disposition.

Pharmacokinetics and Urinary Excretion Mechanism of Orteronel (TAK-700), A Novel 17,20-Lyase Inhibitor, in Animals

S. Asahi, Y. Tagawa, A. Goto, 2015, Drug Research.

The effects of the concentration‐dependent erythrocyte distribution of TAK‐802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics

S. Asahi, Y. Tagawa, A. Goto, 2016, Biopharmaceutics & drug disposition.

Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain.

H. Kusuhara, S. Iwasaki, T. Yoneyama, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Disposition of the Highly Fat Distributed Compound 1-(4-Methoxyphenyl)-4-(2,2,4,6,7-Pentamethyl -2,3-Dihydro-1-Benzofuran-5-yl)Piperazine (TAK-357) in Rats and Dogs

T. Tsukamoto, S. Asahi, T. Wakabayashi, 2016, Drug Research.

Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect.

Masanori Nakakariya, A. Goto, Nobuyuki Amano, 2016, Drug metabolism and pharmacokinetics.

Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood – Brain Barrier of Mice S

H. Kusuhara, Ikumi Chisaki, H. Hirabayashi, 2022 .

DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges

Syunsuke Yamamoto, A. Goto, Y. Moriya, 2024, Drug Metabolism and Pharmacokinetics.